Abstract
The regulations applied to NGTs (New Genomic Techniques, particularly genome editing, e.g. CRISPR) constitute a key point that underlines the place each country wants to give them for developing innovative solutions in human health, animal health and welfare, as well as in plant health and also to confront climate change. Faced with these immense prospects as well as better assessed risks with genome editing, many countries (USA, Japan, Argentina, Brazil, Australia etc.) have decided to deregulate the majority of genome editing products. On contrary, the European Union (EU) after the judgment of the Court of Justice (CJEU) of 2018, indicated that GMO regulations must be applied, found itself isolated. This context has given rise to political and academic debates. Consequently, the European Commission decided to launch a strategic initiative for changing the regulations applied to some editing products for plants only. Some key elements of these issues are proposed here for a better understanding.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
